Abstract:
Antibiotic resistance is a pressing global health challenge, and polymyxins have emerged as the last line of defense against multidrug-resistant Gram-negative (MDR-GRN) bacterial infections. Despite the longstanding utility of colistin, the complexities surrounding polymyxins in terms of resistance mechanisms and pharmacological properties warrant critical attention. This review consolidates current literature, focusing on polymyxins antibacterial mechanisms, resistance pathways, and innovative strategies to mitigate resistance. We are also investigating the pharmacokinetics of polymyxins to elucidate factors that influence their in vivo behavior. A comprehensive understanding of these aspects is pivotal for developing next-generation antimicrobials and optimizing therapeutic regimens. We underscore the urgent need for advancing research on polymyxins to ensure their continued efficacy against formidable bacterial challenges.
摘要:
抗生素耐药性是一个紧迫的全球卫生挑战,多粘菌素已成为抵抗多重耐药革兰氏阴性(MDR-GRN)细菌感染的最后一道防线。尽管粘菌素的作用已久,多粘菌素在抗性机制和药理特性方面的复杂性值得关注。这篇综述巩固了当前的文献,专注于多粘菌素的抗菌机制,阻力途径,以及减轻阻力的创新策略。我们还在研究多粘菌素的药代动力学,以阐明影响其体内行为的因素。全面了解这些方面对于开发下一代抗菌药物和优化治疗方案至关重要。我们强调迫切需要推进对多粘菌素的研究,以确保其对强大的细菌挑战的持续疗效。